Related Experiment Video
Updated: Dec 21, 2025
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing
Haoyu Zou1, Israth Jahan Tuhin1, Masuma Akter Monty1
1Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, P.R. China.
Abstract:
High interleukin 17A (IL-17A) expression in hepatocellular carcinoma (HCC) tissue promotes HCC development. This study explores a method to inhibit HCC growth by neutralizing IL-17A in the HCC microenvironment. A novel type 5 adenoviral vector (Ad5) that carries DNA sequences encoding specific neutralizing IL-17A recombinant antibody fragments was developed in this research. After locally injecting into tumor tissues, the Ad5 transduced into tumor cells. This leads to the expression of the anti-IL-17A recombinant antibody fragments in the HCC tissue and consequently to an inhibition of HCC growth by neutralizing IL-17A. The stability of the antibody fragments was optimized by different structures design. Stable HCC cell lines that secrete IL-17A continuously were constructed, which showed stronger invasion and migration ability than control HCC cell lines. In addition, the enhanced migration and invasion ability were partially reversed by applying the adenoviral vectors. These results suggest that IL-17A might promote HCC growth by enhancing the invasion and migration ability of hepatoma cells. The antibody fragments from Ad5 neutralized IL-17A locally, in turn inhibiting the growth of HCC tumors. In conclusion, the local administration of Ad5 vectors encoding IL-17A-neutralizing antibody fragments provides a new option for HCC immunotherapy.
Insights
This study developed a novel adenoviral vector (Ad5) to deliver IL-17A-neutralizing antibody fragments into hepatocellular carcinoma (HCC) tissue. This approach effectively inhibits HCC tumor growth by neutralizing IL-17A, offering a new immunotherapy option.
Area of Science:
- Oncology
- Immunotherapy
- Gene Therapy
Background:
- High expression of interleukin 17A (IL-17A) is linked to hepatocellular carcinoma (HCC) progression.
- IL-17A may enhance the invasive and migratory capabilities of hepatoma cells, promoting HCC development.
Purpose of the Study:
- To investigate a novel gene therapy approach for inhibiting HCC growth by neutralizing IL-17A within the tumor microenvironment.
- To develop and evaluate a type 5 adenoviral vector (Ad5) encoding specific IL-17A-neutralizing recombinant antibody fragments for HCC immunotherapy.
Main Methods:
- Construction of a novel Ad5 vector carrying DNA sequences for IL-17A-neutralizing recombinant antibody fragments.
- Local injection of Ad5 into HCC tumor tissues to facilitate transduction and expression of antibody fragments.
- Development of stable HCC cell lines secreting IL-17A to assess cell invasion and migration, and the effect of Ad5 treatment.
Main Results:
- Ad5 vectors successfully transduced tumor cells, leading to local expression of anti-IL-17A antibody fragments.
- The expression of antibody fragments neutralized IL-17A, resulting in significant inhibition of HCC tumor growth.
- HCC cell lines engineered to secrete IL-17A exhibited increased invasion and migration, which were partially reversed by Ad5 treatment.
Conclusions:
- IL-17A plays a role in promoting HCC growth, potentially by enhancing hepatoma cell invasion and migration.
- Local administration of Ad5 vectors encoding IL-17A-neutralizing antibody fragments represents a promising new strategy for HCC immunotherapy.
- This gene therapy approach offers a targeted method to neutralize IL-17A within the tumor microenvironment, inhibiting cancer progression.
Related Concept Videos
00:59Gene Therapy
01:27Tumor Immunotherapy